BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27761727)

  • 1. The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.
    Sahin N; Akatli AN; Celik MR; Ulutas H; Samdanci ET; Colak C
    Pathol Oncol Res; 2017 Jul; 23(3):487-491. PubMed ID: 27761727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
    Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
    Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
    Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Pseudomesotheliomatous' carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff.
    Attanoos RL; Gibbs AR
    Histopathology; 2003 Nov; 43(5):444-52. PubMed ID: 14636270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
    Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
    Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC; Chen PC; Chou TY; Chiang H
    Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
    Klebe S; Swalling A; Jonavicius L; Henderson DW
    J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
    Brown RW; Clark GM; Tandon AK; Allred DC
    Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.
    Chaouche-Mazouni S; Scherpereel A; Zaamoum R; Mihalache A; Amir ZC; Lebaïli N; Delaire B; Gosset P
    Ann Diagn Pathol; 2015 Aug; 19(4):193-7. PubMed ID: 25935651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
    Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
    Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
    Miettinen M; Sarlomo-Rikala M
    Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
    Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
    Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
    Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
    Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case reports of primary pulmonary adenocarcinoma with pleural spread: so-called pseudomesotheliomatous adenocarcinoma.
    Saito R; Kasajima A; Taniuchi S; Fujishima F; Ishida K; Nakamura Y; Yamanda S; Takahashi T; Hitomi H; Murakami K; Watanabe M; Sasano H
    Pathol Int; 2012 Oct; 62(10):709-15. PubMed ID: 23005599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
    Dejmek A
    Acta Cytol; 2008; 52(5):579-83. PubMed ID: 18833821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.
    Panjković M; Lovrenski A; Eri Z; Usaj SK; Tegeltija D; Krcedinac J
    Vojnosanit Pregl; 2013 Nov; 70(11):1010-4. PubMed ID: 24397195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.
    Gotzos V; Vogt P; Celio MR
    Pathol Res Pract; 1996 Feb; 192(2):137-47. PubMed ID: 8692714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
    Leers MP; Aarts MM; Theunissen PH
    Histopathology; 1998 Mar; 32(3):209-16. PubMed ID: 9568505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.